Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

NCT00170742 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped trial stopped on Sept 24, 2007

Conditions

Proliferative Diabetic Retinopathy

Interventions

DRUG: Octreotide, 30 mg i.m. LAR formulation

Sponsor

Novartis